Literature DB >> 9373121

Clinically suspected primary acquired nasolacrimal duct obstruction: clinicopathologic review of 150 patients.

N Tucker1, D Chow, F Stockl, F Codère, M Burnier.   

Abstract

PURPOSE: The incidence of lacrimal sac pathology in patients with clinically suspected primary acquired nasolacrimal duct obstruction is unknown. This is an important issue when considering the potential risk of either conservative nonsurgical management or laser dacryocystorhinostomy, neither of which permits direct visualization and biopsy of the lacrimal outflow apparatus.
METHODS: A total of 162 lacrimal sac biopsy specimens were obtained in 150 consecutive patients undergoing external or endonasal dacryocystorhinostomy for clinical primary acquired nasolacrimal duct obstruction from January 1992 to October 1994.
RESULTS: A total of 147 patients (98%) had histopathologic findings consistent with inflammation or fibrosis of the lacrimal sac or both. In the remaining three patients, abnormalities included sarcoid granuloma (one patient), oncocytoma (one patient), and lymphoma (one patient).
CONCLUSIONS: The incidence of significant pathology of the lacrimal sac in clinically suspected primary acquired nasolacrimal duct obstruction is low. However, these cases can be identified correctly only by routine biopsy of the lacrimal sac during dacryocystorhinostomy.

Entities:  

Mesh:

Year:  1997        PMID: 9373121     DOI: 10.1016/s0161-6420(97)30012-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  23 in total

1.  [Selective lacrimal sac biopsy for external dacryocystorhinostomy: a clinical pathological study].

Authors:  L M Heindl; E Treutlein; A G M Jünemann; F E Kruse; L M Holbach
Journal:  Ophthalmologe       Date:  2010-12       Impact factor: 1.059

2.  [Epiphora and conjunctivitis for 6 years].

Authors:  U B Kottler; U Schlötzer-Schrehardt; L M Holbach
Journal:  Ophthalmologe       Date:  2004-07       Impact factor: 1.059

3.  Associated morbidity of nasolacrimal duct obstruction--a large community based case-control study.

Authors:  Arie Y Nemet; Shlomo Vinker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-22       Impact factor: 3.117

Review 4.  Is routine biopsy of the lacrimal sac wall indicated at dacryocystorhinostomy? A prospective study and literature review.

Authors:  C Merkonidis; C Brewis; M Yung; M Nussbaumer
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

Review 5.  A 7-year prospective study of routine histopathological evaluation of the lacrimal sac wall incisional biopsy specimens obtained during external dacryocystorhinostomy in adults and a review of the literature.

Authors:  Miroslav Knežević; M Stojković; M Jovanović; Z Stanković; Dejan M Rašić
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

Review 6.  Clinical significance of routine lacrimal sac biopsy during dacryocystorhinostomy: A comprehensive review of literature.

Authors:  Zoran Koturović; Miroslav Knežević; Dejan M Rašić
Journal:  Bosn J Basic Med Sci       Date:  2017-02-21       Impact factor: 3.363

7.  [Dacryocystorhinostomy as part of the interdisciplinary treatment of lacrimal duct].

Authors:  S Herberhold; R Lindner; K Wilhelm; M Kühnemund; A Schröck; M Jakob; M Förl; E Domeier; T J Mäueler; M S Bedar; S Keiner; A Weißbach
Journal:  HNO       Date:  2013-10       Impact factor: 1.284

8.  Transcanalicular endoscopic dacryoplasty in patients with primary acquired nasolacrimal duct obstruction.

Authors:  Sang Min Lee; Helen Lew
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-03       Impact factor: 3.117

9.  Pyogenic granuloma of the lacrimal sac.

Authors:  Bülent Yazici; Ayşe Tör Ayvaz; Sibel Aker
Journal:  Int Ophthalmol       Date:  2007-11-16       Impact factor: 2.031

10.  Value of microbiology study in congenital nasolacrimal duct obstruction.

Authors:  Yasser H Al-Faky; Tahir Naeem; Nora Al-Sobaie; Reem Al-Huthail; Hessa Al-Odan; Essam A Osman; Ahmad Mousa
Journal:  Saudi J Ophthalmol       Date:  2012-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.